Maria Curcio Bishop
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Maria Curcio Bishop has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Hani M. Babiker
Mayo Clinic, Jacksonville, FL
2 shared publications - Elisa Rogowitz
University of Arizona College of Medicine, 1501 N. Campbell Ave, Tucson, AZ 85724, USA
1 shared publication - Josephine A Taverna
Division of Hematology-Oncology, Department of Medicine, Southern Arizona VA Health Care System, 3601 S 6Th Ave, Tucson, 85723, AZ, USA
1 shared publication Margaret M. Briehl
Department of Pathology, University of Arizona, Tucson, USA
1 shared publication- Mohammed Kanaan
Division of Hematology-Oncology, Department of Medicine, University of Arizona College of Medicine, 1501 North Campbell Avenue, Tucson, AZ 85724, USA
1 shared publication - Paul N Meyer
Division of Hematology-Oncology, Department of Medicine, Southern Arizona VA Health Care System, 3601 S 6Th Ave, Tucson, 85723, AZ, USA
1 shared publication
Latest Publications
- 14 January 2022
- Published by Springer Nature in Journal of Cancer Education
- Vol. 37 (1) , 1-2
A Successful Program to Promote Equity in Cancer Care for American Indians
- 14 January 2022
- Published by Springer Nature in Journal of Cancer Education
- Vol. 37 (1) , 1-2
A Successful Program to Promote Equity in Cancer Care for American Indians
- 2 July 2021
- Published by Springer Nature in Journal of Cancer Education
- Vol. 36 (4) , 1-2
New Programs to Promote Global Cancer Education
- 2 July 2021
- Published by Springer Nature in Journal of Cancer Education
- Vol. 36 (4) , 1-2
New Programs to Promote Global Cancer Education
- Open Access
- 30 October 2020
- Published by Springer Nature in Journal of Cancer Education
- Vol. 35 (6) , 1049-1051
International Cancer Education Conference: Using Cancer Education to Address Social Determinants of Health
- 30 October 2020
- Published by Springer Nature in Journal of Cancer Education
- Vol. 35 (6) , 1049-1051
Open AccessInternational Cancer Education Conference: Using Cancer Education to Address Social Determinants of Health
- 2 January 2020
- Published by Springer Nature in Journal of Cancer Education
- Vol. 35 (1) , 1-2
The Veterans Health Administration’s Contribution to Cancer Education
- 2 January 2020
- Published by Springer Nature in Journal of Cancer Education
- Vol. 35 (1) , 1-2
The Veterans Health Administration’s Contribution to Cancer Education
- 26 July 2019
- Published by Springer Nature in Journal of Cancer Education
- Vol. 34 (4) , 627-628
An Opportunity to Share
- 26 July 2019
- Published by Springer Nature in Journal of Cancer Education
- Vol. 34 (4) , 627-628
An Opportunity to Share
- 1 October 2018
- Published by Springer Nature in Journal of Cancer Education
- Vol. 33 (5) , 945-946
Gifts from the Past
- 1 October 2018
- Published by Springer Nature in Journal of Cancer Education
- Vol. 33 (5) , 945-946
Gifts from the Past
- Open Access
- 5 December 2014
- Published by Springer Nature in Biomarker Research
- Vol. 2 (1) , 1-6
The great masquerader of malignancy: chronic intestinal pseudo-obstruction
Paraneoplastic syndromes can precede the initial manifestation and diagnosis of cancer. Paraneoplastic syndromes are a heterogeneous group of disorders caused by mechanisms other than the local presence of tumor cells. These phenomena are mediated by humoral factors secreted by tumor cells or by tumor mediated immune responses. Among paraneoplastic syndromes, chronic intestinal pseudo-obstruction (CIPO) is rare and represents a particularly difficult clinical challenge. Paraneoplastic CIPO is a highly morbid syndrome characterized by impaired gastrointestinal propulsion with symptoms and signs of mechanical bowel obstruction. Clinical outcomes of paraneoplastic CIPO are often deleterious. The current standard of care for the management of CIPO includes supportive treatment with promotility and anti-secretory agents. However, the majority of patients with CIPO eventually require the resection of the non-functioning gut segment. Here, we present a 62-year-old patient with anti-Hu antibody associated paraneoplastic CIPO and underlying small cell lung cancer who underwent treatment with cisplatin and etoposide. Herein, we discuss diagnosis, prognosis, proposed mechanisms, treatment options, and future potential therapeutic strategies of paraneoplastic CIPO.
- 5 December 2014
- Published by Springer Nature in Biomarker Research
- Vol. 2 (1) , 1-6
Open AccessThe great masquerader of malignancy: chronic intestinal pseudo-obstruction
Paraneoplastic syndromes can precede the initial manifestation and diagnosis of cancer. Paraneoplastic syndromes are a heterogeneous group of disorders caused by mechanisms other than the local presence of tumor cells. These phenomena are mediated by humoral factors secreted by tumor cells or by tumor mediated immune responses. Among paraneoplastic syndromes, chronic intestinal pseudo-obstruction (CIPO) is rare and represents a particularly difficult clinical challenge. Paraneoplastic CIPO is a highly morbid syndrome characterized by impaired gastrointestinal propulsion with symptoms and signs of mechanical bowel obstruction. Clinical outcomes of paraneoplastic CIPO are often deleterious. The current standard of care for the management of CIPO includes supportive treatment with promotility and anti-secretory agents. However, the majority of patients with CIPO eventually require the resection of the non-functioning gut segment. Here, we present a 62-year-old patient with anti-Hu antibody associated paraneoplastic CIPO and underlying small cell lung cancer who underwent treatment with cisplatin and etoposide. Herein, we discuss diagnosis, prognosis, proposed mechanisms, treatment options, and future potential therapeutic strategies of paraneoplastic CIPO.
- Open Access
- 17 July 2014
- Published by Springer Nature in Experimental Hematology & Oncology
- Vol. 3 (1) , 20
Neuroblastoma of the elderly, an oncologist’s nightmare: case presentation, literature review and SEER database analysis
Neuroblastoma is considered a pediatric malignancy as over 95% of cases are diagnosed in patients ≤10 years old. This cancer is extremely rare in elderly patients. We conducted a Surveillance, Epidemiology, and End Results (SEER) database analysis in the USA between 1973–2007 that revealed only 35 elderly patients (>60 years of age) with neuroblastoma of whom only 2 patients had primary mediastinal neuroblastoma. There is a paucity of treatment and survival outcomes data for the elderly owing to the rarity of neuroblastoma in this population. Currently there are no standard guidelines or protocols for treatment of adult neuroblastoma. We report a rare and challenging case of an 86-year old patient presenting with mediastinal neuroblastoma and syndrome of inappropriate antidiuretic hormone secretion (SIADH) successfully treated with resection. Herein, we also provide a review of the literature and updated survival data on neuroblastoma based on results of our SEER database review.
- 17 July 2014
- Published by Springer Nature in Experimental Hematology & Oncology
- Vol. 3 (1) , 20
Open AccessNeuroblastoma of the elderly, an oncologist’s nightmare: case presentation, literature review and SEER database analysis
Neuroblastoma is considered a pediatric malignancy as over 95% of cases are diagnosed in patients ≤10 years old. This cancer is extremely rare in elderly patients. We conducted a Surveillance, Epidemiology, and End Results (SEER) database analysis in the USA between 1973–2007 that revealed only 35 elderly patients (>60 years of age) with neuroblastoma of whom only 2 patients had primary mediastinal neuroblastoma. There is a paucity of treatment and survival outcomes data for the elderly owing to the rarity of neuroblastoma in this population. Currently there are no standard guidelines or protocols for treatment of adult neuroblastoma. We report a rare and challenging case of an 86-year old patient presenting with mediastinal neuroblastoma and syndrome of inappropriate antidiuretic hormone secretion (SIADH) successfully treated with resection. Herein, we also provide a review of the literature and updated survival data on neuroblastoma based on results of our SEER database review.